SR One Capital Management — 2022 Investments
2 investments dated 2022 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company committed to developing best-in-class novel therapy for hypertension treatment.
BiotechRadnor, US
Brian Taylor Slingsby(Director)Olivier Litzka(Director)Derek DiRocco(Director)Adam Levy(Executive Officer)Jon Congleton(Executive Officer, Director)Srinivas Akkaraju(Director)
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)Ivan Trifunovich(Director)John Wesley(Director)
Board seatRajeev Dadoo· per SEC Form D · $80M raise · filed Mar 2022
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.